Theravance Biopharma, Inc. · Brief

Next report

8 days

Nov 9 · after closeest.Q3 FY26

Earnings

Expected move

No implied move.

Implied vs realized

8 reportsHistory

0 of 8≥ implied

avg implied: ±14.5%
avg realized: ±6.1%

Nov 12 '24±12.3%▲+8.64%×0.70

Feb 26 '25±13.8%▲+2.09%×0.15

May 8 '25±12.1%▼−9.29%×0.77

Aug 12 '25±24.8%▲+4.19%×0.17

Q3 FY25±24.6%▲+22.68%×0.92

Q1 FY26±12.0%▲+1.30%×0.11

May 7 '26±10.3%▲+0.47%×0.05

Q2 FY26±6.0%▼−0.12%×0.02

quarterimplied−25%0+25%realized×

Q2 FY26±6.0%▼−0.12%×0.02

May '26±10.3%▲+0.47%×0.05

Q1 FY26±12.0%▲+1.30%×0.11

Q3 FY25±24.6%▲+22.68%×0.92

Aug '25±24.8%▲+4.19%×0.17

May '25±12.1%▼−9.29%×0.77

2 older reports

Feb '25±13.8%▲+2.09%×0.15

Nov '24±12.3%▲+8.64%×0.70

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 9 report · est.

Bull2

8disclosed supplier and customer ties in SEC filingsSEC filings

175managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 4

8 of 8recent reports where the move came in under the options implied rangeEarnings history

9 of 23largest reporting managers who cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

TBPH report session

Customers 1

VTRSViatris×0.21

× = co-movement · max 473dSource: SEC filings · market data

Latest changes

30 daysAll changes

No changes.

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.